156 related articles for article (PubMed ID: 35869779)
1. Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia.
Rohani R; Scheetz MH; Donnelly HK; Donayre A; Kang M; Diaz E; Dedicatoria K; Hauser AR; Ozer EA; Nozick S; Qi C; Pawlowski AE; Neely MN; Misharin AV; Wunderink RG; Rhodes NJ;
J Antimicrob Chemother; 2022 Oct; 77(11):2956-2959. PubMed ID: 35869779
[TBL] [Abstract][Full Text] [Related]
2. Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia.
Alshaer MH; Maranchick N; Bai C; Maguigan KL; Shoulders B; Felton TW; Mathew SK; Mardini MT; Peloquin CA
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0056322. PubMed ID: 35699444
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Heil EL; Nicolau DP; Farkas A; Roberts JA; Thom KA
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967022
[TBL] [Abstract][Full Text] [Related]
4. Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients.
Smekal AK; Furebring M; Eliasson E; Lipcsey M
Sci Rep; 2022 Dec; 12(1):21891. PubMed ID: 36535989
[TBL] [Abstract][Full Text] [Related]
5. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
6. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
[TBL] [Abstract][Full Text] [Related]
8. Individual meropenem epithelial lining fluid and plasma PK/PD target attainment.
Rohani R; Yarnold PR; Scheetz MH; Neely MN; Kang M; Donnelly HK; Dedicatoria K; Nozick SH; Medernach RL; Hauser AR; Ozer EA; Diaz E; Misharin AV; Wunderink RG; Rhodes NJ
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0072723. PubMed ID: 37975660
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
10. Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.
He X; Liu X; Gong X; Wang L; Chen F
Curr Drug Metab; 2023; 24(1):5-15. PubMed ID: 36974414
[TBL] [Abstract][Full Text] [Related]
11. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
[TBL] [Abstract][Full Text] [Related]
12. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
16. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
17. Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in ICU patients: A prospective observational study.
Helset E; Cheng V; Sporsem H; Thorstensen C; Nordøy I; Gammelsrud KW; Hanssen G; Ponzi E; Lipman J; von der Lippe E
Acta Anaesthesiol Scand; 2024 Apr; 68(4):502-511. PubMed ID: 38286568
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease.
Hassanpour R; Ziaie S; Kobarfard F; Kouchek M; Miri M; Ahmadi Koomleh A; Shojaei S; Salarian S; Pourheidar E; Nezarat F; Sistanizad M
Eur J Clin Pharmacol; 2021 Jun; 77(6):831-840. PubMed ID: 33409684
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and Pharmacodynamic Characteristics of Vancomycin and Meropenem in Critically Ill Patients Receiving Sustained Low-efficiency Dialysis.
Oliveira MS; Machado AS; Mendes ET; Chaves L; Perdigão Neto LV; Vieira da Silva C; Cavani Jorge Santos SR; Sanches C; Macedo E; Levin AS
Clin Ther; 2020 Apr; 42(4):625-633. PubMed ID: 32199609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
